In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Status:
RECRUITING
Trial end date:
2026-06-06
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer. Chemotherapy drugs, such as bacillus Calmette-Guerin (BCG), gemcitabine, docetaxel, and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care chemotherapy for non-invasive bladder cancer is usually given directly into the bladder through a catheter (intravesical). This process requires numerous visits and can be disruptive to the lives of patients and caregivers. Bringing cancer care to the patients with in-home intravesical therapy may help reduce the disruption to daily lives. In-home intravesical chemotherapy may be safe and tolerable and may also be preferable to in-clinic administration in patients with non-muscle invasive bladder cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Center for Advancing Translational Sciences (NCATS)
Treatments:
Cystoscopy Docetaxel Gemcitabine Home Care Services House Calls Mitomycin Mitozytrex